FindTrial
Sign In

A pilot study to assess flutamide monotherapy compared With maximal androgen blockade in metastatic prostate cancer

A pilot study to assess flutamide monotherapy compared With maximal androgen blockade in metastatic prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN92984394
Enrollment
Unknown
Registered
2002-08-19
Start date
1994-01-01
Completion date
Unknown
Last updated
2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer Cancer Prostate cancer

Interventions

1. Group A: Oral flutamide 250 mg three times daily 2. Group B: Oral flutamide 250 mg three times daily plus either orchidectomy or the lutenizing hormone releasing hormone (LHRH) anal

Sponsors

Schering-Plough Ltd (UK)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed prostate carcinoma 2. Skeletal metastases on bone scan, with radiological conformation if appropriate, or typical sclerotic metastases on X-ray 3. Life expectancy >6 months 4. Suitable for treatment by any of the study therapies 5. No previous hormonal therapy 6. Not currently receiving corticosteroids, spironolactone or aminoglutethamide 7. Adequate renal and hepatic function

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026